Authors:
Lyudmila Boyanova Department of Medical Microbiology, Medical University of Sofia, Sofia, Bulgaria

Search for other papers by Lyudmila Boyanova in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0001-9622-0873
,
Petyo Hadzhiyski Specialized Hospital for Active Pediatric Treatment, Medical University of Sofia, Sofia, Bulgaria

Search for other papers by Petyo Hadzhiyski in
Current site
Google Scholar
PubMed
Close
,
Rumyana Markovska Department of Medical Microbiology, Medical University of Sofia, Sofia, Bulgaria

Search for other papers by Rumyana Markovska in
Current site
Google Scholar
PubMed
Close
, and
Raina Gergova Department of Medical Microbiology, Medical University of Sofia, Sofia, Bulgaria

Search for other papers by Raina Gergova in
Current site
Google Scholar
PubMed
Close
Restricted access

Abstract

Antibiotic resistance of Helicobacter pylori strains from 106 symptomatic children was evaluated according to EUCAST breakpoints and rate of multidrug resistance (MDR) was analyzed. Overall resistance rates were amoxicillin 7.5%, metronidazole 25.5%, clarithromycin 34.0% and ciprofloxacin 14.1%. There were no significant differences in resistance rates according to patients' age (2–6 and 7–18 years) and sex. Combined resistance rate was 19.8%, including double, triple, and quadruple resistance in 13.2% (14 strains), 5.7% (6) and 0.9% (1) of the strains, respectively. MDR was found in 5.9% (5/84) of the children with gastritis and in two of the four children with celiac disease. The MDR was present in three children aged 4–6 years and in four children aged 10–17 years. The total MDR rate (6.6%) in Bulgarian children in 2012–2021 was higher than those in other studies based on EUCAST breakpoints such as those in pediatric patients in Slovenia in 2011–2014 (3.8%), Lithuania in 2013–2015 (0%) and Spain in 2014–2019 (0%), although being lower than those (20.7% in the untreated and 47.0% in the treated children) in China in 2019. In brief, it is of concern that MDR can strongly limit the choice of H. pylori therapy of one out of fifteen Bulgarian children and that overall resistance to both metronidazole and clarithromycin can hinder the treatment of 15.1% of the pediatric patients. Susceptibility-guided tailored eradication therapy of H. pylori infection should be more frequently implemented in the symptomatic children to avoid risks of both the infection itself and multiple antibiotic treatments.

  • 1.

    Hooi JKY , Lai WY , Ng WK , Suen MMY , Underwood FE , Tanyingoh D , et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017; 153(2): 420429.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Kasahun GG , Demoz GT , Desta DM . Primary resistance pattern of Helicobacter pylori to antibiotics in adult population: a systematic review. Infect Drug Resist 2020; 13: 15671573.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Tsukamoto T , Nakagawa M , Kiriyama Y , Toyoda T , Cao X . Prevention of gastric cancer: eradication of Helicobacter pylori and beyond. Int J Mol Sci 2017; 18(8): 1699.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Megraud F , Bruyndonckx R , Coenen S , Wittkop L , Huang TD , Hoebeke M , et al. European Helicobacter pylori Antimicrobial Susceptibility Testing Working Group. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut 2021; 70(10): 18151822.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Boyanova L , Hadzhiyski P , Kandilarov N , Markovska R , Mitov I . Multidrug resistance in Helicobacter pylori: current state and future directions. Expert Rev Clin Pharmacol 2019; 12(9): 909915.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Boyanova L , Hadzhiyski P . Helicobacter pylori infection is associated with anemia, weight loss or both conditions among Bulgarian children. Acta Microbiol Immunol Hung 2020; 67(4): 239242.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Boyanova L , Gergova G , Nikolov R , Davidkov L , Kamburov V , Jelev C , et al. Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis 2008; 60(4): 409415.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    EUCAST-The European Committee on Antimicrobial Susceptibility Testing . Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0. 2021. Available from: http://www.eucast.org.

    • Search Google Scholar
    • Export Citation
  • 9.

    Adriaenssens N , Bruyndonckx R , Versporten A , Hens N , Monnet DL , Molenberghs G , et al. Quality appraisal of antibiotic consumption in the community, European Union/European Economic Area, 2009 and 2017. J Antimicrob Chemother 2021; 76(12 Suppl 2): ii60ii67.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Manfredi M , Gismondi P , Maffini V , Bizzarri B , Fornaroli F , Madia C , et al. Primary antimicrobial susceptibility changes in children with Helicobacter pylori infection over 13 years in Northern Italy. Gastroenterol Res Pract 2015; 2015: 717349.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Butenko T , Jeverica S , Orel R , Homan M . Antibacterial resistance and the success of tailored triple therapy in Helicobacter pylori strains isolated from Slovenian children. Helicobacter 2017; 22(5): e12400.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Kori M , Yahav J , Berdinstein R , Shmuely H . Primary and secondary antibiotic resistance of Helicobacter pylori in Israeli children and adolescents. Isr Med Assoc J 2017; 19(12): 747750.

    • Search Google Scholar
    • Export Citation
  • 13.

    Mahmoudi S , Mamishi S , Banar M , Keshavarz Valian S , Bahador A , et al. Antibiotic susceptibility of Helicobacter pylori strains isolated from Iranian children: high frequency of A2143G point mutation associated with clarithromycin resistance. J Glob Antimicrob Resist 2017; 10: 131135.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Dargiene G , Kupcinskas J , Jonaitis L , Vezbavicius M , Kadusevicius E , Kupcinskiene E , et al. Primary antibiotic resistance of Helicobacter pylori strains among adults and children in a tertiary referral centre in Lithuania. APMIS 2018; 126(1): 2128.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Famouri F , Emadoleslami MS , Riahi R , Saneian H , Nasri P . The sensitivity of H. pylori in gastric tissue samples of children and adolescents to various antibiotics in center of Iran. Int J Pediatr 2018; 6(12): 86858696.

    • Search Google Scholar
    • Export Citation
  • 16.

    Zhang Y , Wen Y , Xiao Q , Zheng W , Long G , Chen B , et al. Mutations in the antibiotic target genes related to clarithromycin, metronidazole and levofloxacin resistance in Helicobacter pylori strains from children in China. Infect Drug Resist 2020; 13: 311322.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Botija G , García Rodríguez C , Recio Linares A , Campelo Gutiérrez C , Pérez-Fernández E , Barrio Merino A . Antibiotic resistances and eradication rates in Helicobacter pylori infection. An Pediatr (Engl Ed) 2021; S2341-2879(21): 0017900184.

    • Search Google Scholar
    • Export Citation
  • 18.

    Li J , Deng J , Wang Z , Li H , Wan C . Antibiotic resistance of Helicobacter pylori strains isolated from pediatric patients in southwest China. Front Microbiol 2021; 11: 621791.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Jiang HY , Zhang X , Zhou YY , Jiang CM , Shi YD . Infection, antibiotic exposure, and risk of celiac disease: a systematic review and meta-analysis. J Gastroenterol Hepatol 2020; 35(4): 557566.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Mišak Z , Hojsak I , Homan M . Review: Helicobacter pylori in pediatrics. Helicobacter 2019; 24(Suppl 1): e12639.

  • 21.

    Shamaly H , Berkowitz D , Rosenthal E , Naveh Y . Efficacy of bismuth-based triple therapy in children with abdominal pain and Helicobacter pylori gastritis. J Pediatr Gastroenterol Nutr 2000; 30(2): 198200.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22.

    Yu L , Luo L , Long X , Liang X , Ji Y , Graham DY , Lu H . High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: a randomized trial. Helicobacter 2019; 24(4): e12596.

    • Search Google Scholar
    • Export Citation
  • 23.

    Schwarzer A , Urruzuno P , Iwańczak B , Martínez-Gómez MZ , Kalach N , Roma-Giannikou E , et al. ESPGHAN Working Group on Helicobacter pylori infection. New effective treatment regimen for children infected with a double-resistant Helicobacter pylori strain. J Pediatr Gastroenterol Nutr 2011; 52(4): 424428.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    Kiyotoki S , Nishikawa J , Sakaida I . Efficacy of vonoprazan for Helicobacter pylori eradication. Intern Med 2020; 59(2): 153161. https://doi.org/10.2169/internalmedicine.2521-18.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25.

    Kusano C , Gotoda T , Suzuki S , Ikehara H , Moriyama M . Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children. J Gastroenterol 2018; 53(6): 718724.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26.

    Kakiuchi T , Yamamoto K , Imamura I , Hashiguchi K , Kawakubo H , Yamaguchi D , et al. Gut microbiota changes related to Helicobacter pylori eradication with vonoprazan containing triple therapy among adolescents: a prospective multicenter study. Sci Rep 2021; 11(1): 755.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Collapse
  • Expand

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • CABELLS Journalytics
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded

2023  
Web of Science  
Journal Impact Factor 1.3
Rank by Impact Factor Q4 (Immunology)
Journal Citation Indicator 0.31
Scopus  
CiteScore 2.3
CiteScore rank Q3 (Infectious Diseases)
SNIP 0.389
Scimago  
SJR index 0.308
SJR Q rank Q3

Acta Microbiologica et Immunologica Hungarica
Publication Model Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article (only for OA publications)
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2025 Online subsscription: 772 EUR / 848 USD
Print + online subscription: 860 EUR / 944 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation
1954
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Aug 2024 42 0 0
Sep 2024 49 0 0
Oct 2024 119 1 1
Nov 2024 77 0 0
Dec 2024 40 0 0
Jan 2025 59 0 0
Feb 2025 20 0 0